Francesca Gottardi

Abstract Haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PTCy) is a viable option for patients lacking a matched donor. In this setting, early inflammatory complications (EICs), such as cytokine release syndrome (CRS) and engraftment syndrome (ES), represent significant complications. Their risk factors and clinical impact, particularly in pediatric populations, remain poorly defined.

D.Leardini, A.Di Battista, F.Gottardi, et al., “Thrombopoietin Receptor Agonists for Treating Poor Graft Function and Thrombocytopenia Post-Autologous Stem Cell Transplantation in Children,” European Journal of Haematology (2026): 1–3, https://doi.org/10.1111/ejh.70154. No abstract is available for this article. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.

INTRODUCTION Allogeneic haematopoietic cell transplantation (HCT) is an effective treatment for many high-risk or relapsed paediatric haematological malignancies (HM).1-4 The outcome of HCT in children has progressively improved over the years, due to advancements in transplant techniques.5, 6 However, some patients experience a treatment failure, mainly due to post-transplant disease relapse7, 8 or, less frequently, to either primary or secondary graft failure (GF).9 Both disease recurrence...